skip to primary navigationskip to content

Dr Simon Buczacki

Simon Buczacki 2019 

   Dr Simon Buczacki


   Colorectal cancer cell identity and tumour evolution


   Departmental Affiliation: Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre


Simon Buczacki is an academic consultant colorectal surgeon at Addenbrooke's Hospital, Cambridge. He undertook his clinical training in Cambridge which included a PhD at the CRUK Cambridge Institute. His post-doctoral scientific training was within the lab of Doug Winton funded by a CRUK Intermediate Fellowship. He is currently funded by a CRUK/RCSEng Advanced Clinician Scientist Fellowship. He co-leads the Aero-Digestive Cancer programme for the Cambridge Cancer Centre and is a fellow and Director of Studies for Medicine at Clare College. His clinical interests lie in the rational application of minimally and maximally invasive cancer surgery and he has a sub-specialty interest in intestinal neuro-endocrine tumour surgery.

External links


Buczacki research 2018

Image credit: Simon Buczacki


The Buczacki lab is interested primarily in the role sub-clonal interactions play on colorectal cancer cell identity and behaviour. We believe that the behaviour of normal intestinal cells is often analogous to that seen in oncogenically transformed cells and thus, we also study the behaviour of progenitor and differentiated cells from normal intestinal tissues to provide insights into cancer cell behaviour. We are particularly interested in understanding the mechanisms and links behind cancer plasticity and identity switching. The lab is also interested in understanding the fundamental biology of small intestinal neuro-endocrine tumours through organoid biology and mouse modelling.

Plain English

Our lab uses human samples from bowel cancer surgical resections to understand why cancer cells from the same tumour can behave in different ways. We believe that how a cancer cell functions and proliferates is intimately related to how it interacts with neighbouring cells rather than being directly determined by the mutations the cell has acquired. We translate our findings for patient benefit through the identification of novel drug targets.

Key Publications